Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.

Curr Rheumatol Rep · 2018 · PMC6097048 · PMID 30094742

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

ACR20 and ACR50 at week 52 showed a trend of superior response in both SB5 and SB5/RP-switch groups compared to the RP group, using the PPS (upper limit of CI: 15.9%, exceeding ± 15%) but not using FAS [ 52 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.